Brief: Hbm Holdings Says Unit Entering T-Cell Engager Discovery Collaboration With Candid Therapeutics
16/12/2024 15:33
Dec 16 (Reuters) - Hbm Holdings Ltd 2142.HK :
* UNIT ENTERING T-CELL ENGAGER DISCOVERY COLLABORATION WITH
CANDID
THERAPEUTICS
* NONA BIOSCIENCES WILL BE ELIGIBLE TO RECEIVE UPFRONT AND
POTENTIAL MILESTONE PAYMENTS OF UP TO US$320 MILLION
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study